Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-26

Clinical Trial Update: Treatment of Adult Ph+ LAL With BMS-354825 [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates dasatinib (BMS-354825) in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sprycel (dasatinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Lymphoblastic Leukemia, Acute | Phase 2 | Status: COMPLETED | Results posted: 2015-01-26